Biotech
Biogen, Genentech's Rituxan Fails New Study
04/29/08 - 10:12 AM EDT
The drug Rituxan failed to benefit patients with lupus, according to negative results from a late-stage study announced Tuesday by the drug's partners, Genentech DNA and Biogen Idec BIIB. This is the second clinical setback for Rituxan in the last two weeks. On April 15, the companies announced that a late-stage study in primary progressive multiple sclerosis also failed. In this most recent study, patients with systemic lupus erythematosus (SLE), commonly called lupus, failed to respond any better to Rituxan vs. placebo after one year of treatment, the companies said. None of the study's six secondary endpoints were successful, either. A separate phase III study of Rituxan in patients with lupus nephritis, a different form of the disease, is ongoing. Lupus has proven to be a stubborn disease to overcome, leaving in its wake a long list of clinical trial failures. With that said, most analysts did not include Rituxan-lupus revenue in their financial models for either Genentech or Biogen Idec. However, lupus and multiple sclerosis were seen as long-term growth opportunities for Rituxan, so the recent study failures take a bite out of that prospect. Genentech and Biogen Idec reported 2007 Rituxan sales of $2.29 billion in the U.S., primarily as a treatment for the blood cancer non-Hodgkin's lymphoma. The drug is also approved to treat rheumatoid arthritis. Genentech shares were down 5.8% at $68.93 in early trading Tuesday. Biogen Idec was trading down 5% at $61.43. Know What You Own: Genentech has a deep cancer drug pipeline, with about 15 experimental drugs in phase I, II or III trials. Among the biotech company's cancer drug partners are Curis CRIS, Immunogen IMGN, Abbott Labs ABT, Seattle Genetics SGEN and Exelixis EXEL.
Data presented this weekend show telaprevir is the leader.
What to expect when ImClone presents the latest Erbitux data at ASCO in June.
Regulatory demands will result in delays for cholesterol-lowering candidate Mipomersen. Isis gets a downgrade on the news.
Apple and AT&T were among the most searched stocks on TheStreet.com Friday. Here's what Cramer had to say about them recently.
Catch up on his thinking on the hottest topics of the past week.
Investors will have to deal with a Fed meeting and another flood of earnings and economic data.
Looking for deep value with Defiance Asset Management, polling big investors about where the market's headed, plus much more.
See who made what calls.
3 Stocks I Saw On TVDan Fitzpatrick examines three stocks viewed on Fast Money and Mad Money Today's stocks include Deere & Co., Petrobras and MBIA
TheStreet.com Ratings checks in on First Community Bancorp and First Niagara Financial Group two months after recommending the stock.
Take-Two's latest hit receives a perfect score from industry reviewers.
- Cramer's 'Mad Money' Recap: Mad Money's Rally Playbook
- The Polycarbonate Price Cut
- CalPERS Pushes for Clean House at Standard Pacific
- Investing in China: What You Need to Know
- Coming Week: 'Glimmer of Hope'
- Top Stocks With Insider Buying, Buybacks
- New Solar ETF Helps Spread Sector's Risk
- Feuerstein's Biotech-Stock Mailbag
- Need to Own Energy? Here's How to Do It
- My Company Doesn't Provide Health Insurance (Gulp!)
Sponsored by:

BEAT THE STREET GAME:


